Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2005058967) NOVEL ANTI-INSULIN/IGF-I HYBRID RECEPTOR OR ANTI-INSULIN/IGF-I HYBRID RECEPTOR AND IGF-IR ANTIBODIES AND USES THEREOF
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2005/058967 International Application No.: PCT/IB2004/004360
Publication Date: 30.06.2005 International Filing Date: 16.12.2004
IPC:
A61K 39/395 (2006.01) ,A61K 47/48 (2006.01) ,C07K 16/28 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
48
the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants:
PIERRE FABRE MEDICAMENT [FR/FR]; 45, place Abel-Gance F-92100 Boulogne Billancourt, FR (AllExceptUS)
GOETSCH, Liliane [FR/FR]; FR (UsOnly)
CORVAIA, Nathalie [FR/FR]; FR (UsOnly)
DUFLOS, Alain [FR/FR]; FR (UsOnly)
HAEUW, Jean-François [FR/FR]; FR (UsOnly)
LEGER, Olivier [FR/FR]; FR (UsOnly)
BECK, Alain [FR/FR]; FR (UsOnly)
Inventors:
GOETSCH, Liliane; FR
CORVAIA, Nathalie; FR
DUFLOS, Alain; FR
HAEUW, Jean-François; FR
LEGER, Olivier; FR
BECK, Alain; FR
Agent:
MARTIN, Jean-Jacques; Cabinet Regimbeau 20, rue de Chazelles Cedex 17 F-75847 Paris, FR
Priority Data:
10/735,91616.12.2003US
Title (EN) NOVEL ANTI-INSULIN/IGF-I HYBRID RECEPTOR OR ANTI-INSULIN/IGF-I HYBRID RECEPTOR AND IGF-IR ANTIBODIES AND USES THEREOF
(FR) NOUVEAU RECEPTEUR HYBRIDE ANTI-INSULINE/IGF-I OU RECEPTEUR HYBRIDE ANTI-INSULINE/IGF-I ET ANTICORPS IGF-IR ET APPLICATIONS
Abstract:
(EN) The present invention relates to antibodies capable of binding specifically to i) the human anti-insulin/IGF-I hybrid receptor (hybrid-R) or ii) both to said hybrid-R and the human insulin-like growth factor I receptor (IGF-IR) and/or capable of specifically inhibiting the tyrosine kinase activity of said hybrid-R or both hybrid-R and IGF-IR, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing, or with an abnormal activation of, hybrid-R or of both hybrid-R and IGF-IR or any pathology connected with the overexpression, or abnormal activation, of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the hybrid-R or both hybrid-R and IGF-IR. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
(FR) La présente invention se rapporte à de nouveaux anticorps pouvant se lier spécifiquement (i) au récepteur hybride anti-insuline/IGF-I humain (R hybride) ou (ii) à la fois audit R hybride et au récepteur du facteur de croissance insulinoïde I humain (IGF-IR), et/ou étant apte à inhiber spécifiquement l'activité tyrosine kinase dudit R hybride ou à la fois du R hybride et de IGF-IR, et notamment à des anticorps monoclonaux d'origine murine, chimérique et humanisée, ainsi qu'aux séquences d'acides aminés et d'acides nucléiques codant pour ces anticorps. En outre, l'invention se rapporte à l'application de ces anticorps comme médicament dans le traitement et/ou la prévention des cancers à surexpression, ou à activation anormale, de R hybride ou à la fois de R hybride et de IGF-IR, ou de toute pathologie liée à cette surexpression ou à cette activation anormale, dudit récepteur, ainsi que dans des procédés et des trousses de diagnostic de maladies liées à la surexpression de R hybride ou à la fois de R hybride et de IGF-IR. Enfin, l'invention se rapporte à des produits et/ou compositions comportant des anticorps de ce type en association avec des anticorps anti-EGFR et/ou des composés et/ou des agents anti-cancéreux ou des agents conjugués avec des toxines, et leur application au traitement et/ou à la prévention de certains cancers.
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)